Ulcerative colitis （UC）， a chronic relapsing inflammatory bowel disease， involves multifaceted pathological mechanisms such as intestinal barrier dysfunction， immune dysregulation， and oxidative stress. Current therapeutic strategies remain limited in efficacy and safety. In recent years， the adenosine monophosphate-activated protein kinase （AMPK） signaling pathway has emerged as a pivotal therapeutic target for UC due to its central role in energy metabolism， inflammatory regulation， and intestinal homeostasis. This article systematically reviewed the mechanisms by which traditional Chinese medicine （TCM） prevented and treated UC through the regulation of the AMPK signaling pathway， with a focus on elucidating AMPK's multidimensional regulatory network in inflammatory signaling crosstalk， alleviating oxidative stress， restoring intestinal immune balance， repairing the intestinal barrier， and modulating gut microbiota. Leveraging its unique advantages of multi-target engagement and low toxicity， TCM demonstrates promising potential in UC treatment and has become a focal area of research. By systematically summarizing and synthesizing the existing literature on TCM-mediated AMPK pathway modulation in UC， this review aims to provide a theoretical foundation for advancing mechanistic research and clinical interventions in UC.

Ulcerative colitis （UC）， a chronic， non-specific inflammatory bowel disease with typical symptoms such as abdominal pain， diarrhea， and bloody stools， demonstrates a high relapse rate and difficulty in curing. Sishenwan， first recorded in Internal Medicine Abstract （Nei Ke Zhai Yao）， are a classic prescription for treating diarrhea caused by deficiency of the spleen and kidney Yang. The core therapeutic principle of Sishenwan is warming and tonifying the spleen and kidney， and astringing the intestine and stopping diarrhea. In recent years， Sishenwan have demonstrated distinct advantages in the clinical treatment of UC. The pathogenesis of UC involves multiple factors， including immune dysregulation and gut microbiota imbalance. Although Western medicine is effective in the short term， its side effects， high relapse rate， and resistance associated with long-term use pose substantial challenges. Sishenwan have shown excellent clinical outcomes in the treatment of UC due to deficiency of the spleen and kidney Yang. Modern clinical studies indicate that Sishenwan， used alone or in combination with Western medicine or other Chinese medicine compound prescriptions， significantly improve the clinical efficacy in treating UC due to deficiency of the spleen and kidney Yang. Sishenwan effectively alleviate core symptoms such as mucus， pus， and blood in stools， and persistent abdominal pain， reduce Mayo scores and the relapse rate， and improve patients' quality of life. Research on the material basis reveals that Sishenwan contain multiple active ingredients such as psoralen， isopsoralen， and evodiamine. Mechanism studies indicate that Sishenwan inhibit the inflammatory cascade reactions by regulating the signal network through multiple targets. Sishenwan regulate cellular immunity and restore intestinal immune homeostasis. At the microecological level， Sishenwan promote the intestinal barrier repair through the "microbiota-metabolism-immunity" axis. The current research still needs to be deepened in aspects such as the mining of specific biomarkers for syndromes and the exploration of the collaborative mechanism of traditional Chinese and Western medicine. In the future， a full-chain system covering syndrome differentiation， targeting， and monitoring needs to be constructed for promoting the paradigm transformation of Sishenwan into precision drugs. This review systematically explains the treatment mechanism of Sishenwan regarding the combination of disease and syndrome and its multi-target regulatory characteristics， providing a theoretical basis and transformation direction for the treatment of UC with integrated traditional Chinese and Western medicine.

Ulcerative colitis （UC）， a chronic， non-specific inflammatory bowel disease with typical symptoms such as abdominal pain， diarrhea， and bloody stools， demonstrates a high relapse rate and difficulty in curing. Sishenwan， first recorded in Internal Medicine Abstract （Nei Ke Zhai Yao）， are a classic prescription for treating diarrhea caused by deficiency of the spleen and kidney Yang. The core therapeutic principle of Sishenwan is warming and tonifying the spleen and kidney， and astringing the intestine and stopping diarrhea. In recent years， Sishenwan have demonstrated distinct advantages in the clinical treatment of UC. The pathogenesis of UC involves multiple factors， including immune dysregulation and gut microbiota imbalance. Although Western medicine is effective in the short term， its side effects， high relapse rate， and resistance associated with long-term use pose substantial challenges. Sishenwan have shown excellent clinical outcomes in the treatment of UC due to deficiency of the spleen and kidney Yang. Modern clinical studies indicate that Sishenwan， used alone or in combination with Western medicine or other Chinese medicine compound prescriptions， significantly improve the clinical efficacy in treating UC due to deficiency of the spleen and kidney Yang. Sishenwan effectively alleviate core symptoms such as mucus， pus， and blood in stools， and persistent abdominal pain， reduce Mayo scores and the relapse rate， and improve patients' quality of life. Research on the material basis reveals that Sishenwan contain multiple active ingredients such as psoralen， isopsoralen， and evodiamine. Mechanism studies indicate that Sishenwan inhibit the inflammatory cascade reactions by regulating the signal network through multiple targets. Sishenwan regulate cellular immunity and restore intestinal immune homeostasis. At the microecological level， Sishenwan promote the intestinal barrier repair through the "microbiota-metabolism-immunity" axis. The current research still needs to be deepened in aspects such as the mining of specific biomarkers for syndromes and the exploration of the collaborative mechanism of traditional Chinese and Western medicine. In the future， a full-chain system covering syndrome differentiation， targeting， and monitoring needs to be constructed for promoting the paradigm transformation of Sishenwan into precision drugs. This review systematically explains the treatment mechanism of Sishenwan regarding the combination of disease and syndrome and its multi-target regulatory characteristics， providing a theoretical basis and transformation direction for the treatment of UC with integrated traditional Chinese and Western medicine.

Objective To observe the therapeutic effect of Suoquan Runchang Prescription for senile mice with constipation and its mechanism of action.Methods Senile Kunming mice were randomly divided into constipation group,Suoquan Runchang Prescription group,ISCK03[stem cell factor(SCF),receptor tyrosine kinase(c-Kit)signaling pathway inhibitor]group,Suoquan Runchang Prescription+ISCK03 group,and normal group,with 12 mice in each group.Except for the normal group,a constipation model was constructed by gavage of 150 mg/kg Compound Diphenoxylate Suspension in all groups of senile Kunming mice.After successful modeling,each group was treated for two weeks.At the end of the intervention,the fecal particles count and fecal water content were detected,the serum levels of interleukin(IL)-1β,IL-6,motilin,gastrin,5-hydroxytryptamine(5-HT),and vasoactive intestinal peptide(VIP)were detected by enzyme-linked immunosorbent assay(ELISA),and the changes in gastric emptying rate and small intestine propulsion rate were determined,the pathologic changes of colonic tissues were detected by hematoxylin-eosin(HE)staining,and protein expressions of SCF and c-Kit in the colonic tissues was detected by Western Blot.Results Compared with the normal group,the disrupted cellular structure,thinner muscle layer,damaged mucosal epithelium were seen in the constipation group,and the fecal particle count,fecal water content,serum motilin,gastrin and 5-HT levels,gastric emptying rate,small intestine propulsion rate,the protein expression levels of SCF and c-Kit in colonic tissues were decreased,and the serum IL-1 β,IL-6 and VIP levels were increased,the differences being statistically significant(P＜0.05).Compared with the constipation group,the colonic tissues damage were improved in Suoquan Runchang Prescription group,the fecal particle count,fecal water content,serum motilin,gastrin and 5-HT levels,gastric emptying rate,small intestine propulsion rate,protein expression levels of SCF and c-Kit in colonic tissues were elevated,the serum IL-1β,IL-6 and VIP levels were decreased,the difference being statistically significant(P＜0.05).The indexes mentioned above in mice of ISCK03 group versus to the results of Suoquan Runchang Prescription group(P＜0.05).Compared with Suoquan Runchang Prescription group,the colonic tissues damage showed aggravated in Suoquan Runchang Prescription+ISCK03 group,and the fecal particle count,fecal water content,serum motilin,gastrin and 5-HT levels,gastric emptying rate,small intestine propulsion rate,protein expression levels of SCF and c-Kit in colonic tissues were decreased,the serum IL-1β,IL-6 and VIP levels were increased,the difference being statistically significant(P＜0.05).Conclusion Suoquan Runchang Prescription can effectively improve constipation in senile mice,and its therapeutic effect maybe related to the up-regulation of SCF,c-Kit expression,thus promoting intestinal peristalsis.

Diabetic foot ulcer(DFU)is one of the severe complications of diabetes mellitus,which often leads to amputation and seriously impairs patients' quality of life.It has complex etiology,involving vascular disease,neuropathy,and infection,etc.,and western medical treatment options are limited.In traditional Chinese medicine(TCM),DFU is classified as"tuoju"(gangrene of the extremities).Simiao Yong'an Decoction,a commonly used formula,has demonstrated clinical effects in improving blood flow,repairing nerves,controlling infection,and promoting wound healing.This article reviewed the TCM pathogenesis of DFU and the clinical and experimental research progress of Simiao Yong'an Decoction,aiming to provide a scientific basis for its treatment.